Predictive Oncology Financials
POAI Stock | USD 1.45 0.10 6.45% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 1.36 | 2.3 |
|
|
The essential information of the day-to-day investment outlook for Predictive Oncology includes many different criteria found on its balance sheet. An individual investor should monitor Predictive Oncology's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Predictive Oncology.
Net Income |
|
Predictive | Select Account or Indicator |
Predictive Oncology Stock Summary
Predictive Oncology competes with Sharps Technology, Microbot Medical, Nexgel, Pro Dex, and Innovative Eyewear. Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US74039M2008 |
CUSIP | 74039M200 74039M309 83084T606 74033P100 83084T309 74039M101 83084T408 09071P109 |
Location | Minnesota; U.S.A |
Business Address | 91 43rd Street, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.predictive-oncology.com |
Phone | (412) 432 1500 |
Currency | USD - US Dollar |
Predictive Oncology Key Financial Ratios
Return On Equity | -1.49 | ||||
Operating Margin | (11.44) % | ||||
Price To Sales | 5.91 X | ||||
Revenue | 1.78 M | ||||
Gross Profit | 1.05 M |
Predictive Oncology Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 13.1M | 43.8M | 25.7M | 14.4M | 16.6M | 9.5M | |
Other Current Liab | 2.9M | 1.4M | 2.1M | 1.6M | 1.9M | 1.6M | |
Net Debt | 5.2M | (27.3M) | (21.9M) | (5.9M) | (5.3M) | (5.0M) | |
Retained Earnings | (108.4M) | (128.0M) | (153.8M) | (167.8M) | (151.0M) | (143.4M) | |
Accounts Payable | 1.4M | 1.0M | 943.5K | 1.3M | 1.5M | 1.1M | |
Cash | 678.3K | 28.2M | 22.1M | 8.7M | 10.0M | 10.5M | |
Other Current Assets | 289.5K | 513.8K | 526.8K | 521.7K | 600.0K | 630.0K | |
Total Liab | 10.4M | 3.5M | 4.0M | 6.1M | 7.1M | 4.6M | |
Total Current Assets | 1.5M | 29.5M | 23.4M | 10.1M | 11.6M | 12.2M | |
Short Term Debt | 5.0M | 639.7K | 188.5K | 667.8K | 768.0K | 1.4M | |
Intangible Assets | 3.4M | 4.0M | 253.9K | 252.5K | 290.3K | 275.8K | |
Common Stock | 198.0K | 656.1K | 787.6K | 40.6K | 36.6K | 34.7K | |
Net Receivables | 256.9K | 354.2K | 331.2K | 333.7K | 383.8K | 270.7K | |
Inventory | 289.5K | 387.7K | 430.5K | 494.4K | 568.5K | 299.1K | |
Net Tangible Assets | (8.1M) | (3.6M) | 29.4M | 21.5M | 24.7M | 26.0M | |
Net Invested Capital | 7.1M | 40.3M | 21.8M | 8.4M | 9.7M | 15.4M | |
Net Working Capital | (7.8M) | 26.2M | 19.5M | 6.1M | 7.0M | 5.2M | |
Capital Stock | 198.8K | 656.9K | 788.4K | 41.4K | 47.6K | 45.3K |
Predictive Oncology Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | 527.5K | 27.5M | (6.1M) | (13.3M) | (15.3M) | (14.6M) | |
Free Cash Flow | (12.6M) | (13.2M) | (12.8M) | (13.5M) | (12.1M) | (11.5M) | |
Depreciation | 1.0M | 1.3M | 1.3M | 739.3K | 850.2K | 892.7K | |
Other Non Cash Items | 13.8M | 1.2M | 11.2M | 452.8K | 520.7K | 494.7K | |
Capital Expenditures | 360.8K | 962.3K | 475.7K | 302.4K | 347.7K | 199.3K | |
Net Income | (25.9M) | (19.7M) | (25.7M) | (14.0M) | (12.6M) | (13.2M) | |
End Period Cash Flow | 678.3K | 28.2M | 22.1M | 8.7M | 10.0M | 10.5M | |
Change To Inventory | (94.7K) | (98.1K) | (42.8K) | (63.9K) | (57.5K) | (54.6K) | |
Investments | (167.5K) | (10.6M) | (475.7K) | (373.3K) | (335.9K) | (352.7K) | |
Change To Netincome | 6.1M | 12.6M | 7.1M | 11.2M | 12.9M | 13.5M |
Predictive Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Predictive Oncology's current stock value. Our valuation model uses many indicators to compare Predictive Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Predictive Oncology competition to find correlations between indicators driving Predictive Oncology's intrinsic value. More Info.Predictive Oncology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Predictive Oncology's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Predictive Oncology's earnings, one of the primary drivers of an investment's value.Predictive Oncology Systematic Risk
Predictive Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Predictive Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Predictive Oncology correlated with the market. If Beta is less than 0 Predictive Oncology generally moves in the opposite direction as compared to the market. If Predictive Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Predictive Oncology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Predictive Oncology is generally in the same direction as the market. If Beta > 1 Predictive Oncology moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Predictive Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Predictive Oncology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Predictive Oncology growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Predictive Oncology January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Predictive Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Predictive Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Predictive Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Predictive Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Predictive Oncology's daily price indicators and compare them against related drivers.
Downside Deviation | 7.49 | |||
Information Ratio | 0.1475 | |||
Maximum Drawdown | 78.21 | |||
Value At Risk | (10.58) | |||
Potential Upside | 16.54 |
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
CEOs Directory Screen CEOs from public companies around the world |